HC Wainwright Decreases Earnings Estimates for Disc Medicine

Key Points

• HC Wainwright trimmed Disc Medicine’s Q3 2026 EPS estimate to a loss of $1.71 from $1.70, while forecasting full-year 2026 EPS of negative $6.64. The firm maintained its Buy rating and $120 price target.
• Disc Medicine reported a quarterly loss of $1.54 per share, beating the consensus estimate of a $1.71 loss by $0.17.
• Analyst sentiment remains broadly positive, with a consensus rating of Moderate Buy and an average price target of $106; institutional investors own 83.7% of the company, while insiders have recently sold shares.

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Equities research analysts at HC Wainwright cut their Q3 2026 earnings estimates for shares of Disc Medicine in a note issued to investors on Thursday, August 6th. HC Wainwright analyst D. Tsao now expects that the company will earn ($1.71) per share for the quarter, down from their previous forecast of ($1.70). HC Wainwright currently has a "Buy" rating and a $120.00 target price on the stock. The consensus estimate for Disc Medicine's current full-year earnings is ($6.61) per share. HC Wainwright also issued estimates for Disc Medicine's Q4 2026 earnings at ($1.74) EPS, FY2026 earnings at ($6.64) EPS, FY2027 earnings at ($6.47) EPS and FY2028 earnings at ($4.62) EPS.

Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported ($1.54) EPS for the quarter, beating the consensus estimate of ($1.71) by $0.17.

IRON has been the topic of several other research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Disc Medicine in a research report on Friday, July 17th. Morgan Stanley upped their target price on Disc Medicine from $80.00 to $85.00 and gave the company an "overweight" rating in a report on Monday, June 15th. Wedbush reaffirmed an "outperform" rating and set a $88.00 price target on shares of Disc Medicine in a research report on Wednesday, June 10th. Finally, Wall Street Zen upgraded Disc Medicine from a "sell" rating to a "hold" rating in a report on Saturday, August 1st. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $106.00.

Disc Medicine Stock Performance

Shares of IRON stock opened at $77.44 on Monday. Disc Medicine has a 52-week low of $40.00 and a 52-week high of $99.50. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.14 and a current ratio of 24.14. The company has a 50-day simple moving average of $73.59 and a two-hundred day simple moving average of $69.78. The company has a market capitalization of $2.96 billion, a price-to-earnings ratio of -11.77 and a beta of 1.00.

Hedge Funds Weigh In On Disc Medicine

A number of hedge funds and other institutional investors have recently bought and sold shares of IRON. BlackRock Inc. bought a new stake in shares of Disc Medicine during the 2nd quarter worth $180,502,000. RA Capital Management L.P. increased its stake in Disc Medicine by 25.3% in the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company's stock valued at $156,925,000 after acquiring an additional 399,026 shares during the last quarter. Vanguard Group Inc. increased its stake in Disc Medicine by 22.1% in the fourth quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company's stock valued at $140,371,000 after acquiring an additional 319,621 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Disc Medicine by 28.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company's stock valued at $134,839,000 after purchasing an additional 371,576 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in Disc Medicine by 110.0% during the fourth quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company's stock valued at $125,557,000 after purchasing an additional 828,248 shares in the last quarter. Hedge funds and other institutional investors own 83.70% of the company's stock.

Insider Buying and Selling at Disc Medicine

In related news, CEO John D. Quisel sold 34,000 shares of the company's stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $70.21, for a total value of $2,387,140.00. Following the transaction, the chief executive officer directly owned 226,064 shares in the company, valued at approximately $15,871,953.44. This represents a 13.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Jonathan Yen-Wen Yu sold 18,612 shares of the firm's stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $69.19, for a total transaction of $1,287,764.28. Following the completion of the sale, the chief operating officer directly owned 54,324 shares in the company, valued at $3,758,677.56. This represents a 25.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 110,712 shares of company stock worth $7,997,536 over the last three months. 3.76% of the stock is currently owned by insiders.

Key Disc Medicine News

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: HC Wainwright raised its price target for Disc Medicine to $120 from $118 and maintained a Buy rating. The new target is well above recent trading levels and may support upside expectations. Price target article
• Positive Sentiment: HC Wainwright modestly improved its estimates for several periods, including FY2026 EPS to a loss of $6.64 from $6.72, Q4 2026 to a loss of $1.74 from $1.75 and FY2028 to a loss of $4.62 from $4.64. The revisions indicate slightly better expected results, although the company remains unprofitable. Earnings estimates article
• Neutral Sentiment: The analyst also lowered its FY2027 EPS forecast to a loss of $6.47 from $6.13 and trimmed its Q3 2026 estimate slightly to a loss of $1.71 from $1.70. Overall, the changes are limited and do not alter HC Wainwright’s Buy rating or $120 target.
• Negative Sentiment: Rosen Law Firm announced an ongoing investigation into potential securities claims alleging that Disc Medicine may have issued materially misleading information to investors. The announcement does not establish wrongdoing, but it adds legal and reputational uncertainty and could pressure the stock if additional claims or disclosures emerge. Rosen Law Firm investigation article
• Negative Sentiment: Insider Rahul Khara sold 5,000 shares for approximately $400,000, reducing his holdings by 8.72%. He continues to own a substantial position, so the sale may reflect portfolio or personal financial considerations, but it can still weigh on investor confidence. Insider selling article

Disc Medicine Company Profile

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source